About: Katja Weisel

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Katja Weisel Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

German oncologist

Attributes	Values
rdf:type	Item
description	Forscher (de) chercheur (fr) дослідник (uk) 研究者 (zh) 研究員 (ja) onderzoeker (nl) German oncologist (en) oncóloga alemana (es) طبيبة أورام ألمانية (ar)
rdfs:label	Katja Weisel (en) Katja Weisel (nl) Katja Weisel (ast)
skos:prefLabel	Katja Weisel (en) Katja Weisel (nl) Katja Weisel (ast)
name	Katja Weisel (en) Katja Weisel (nl) Katja Weisel (ast)
given name	wds:Q96475433-8E1D0EA0-AAA5-41D2-BDEC-36A30F09E5D9
given name	Katja
instance of	wds:Q96475433-6B4C312E-E6A9-4C5D-8ED1-7111ACE8CB83
instance of	Homo sapiens
skos:altLabel	Katja C. Weisel (en) Katja Christina Weisel (en)
occupation	wds:Q96475433-34E92EE2-E150-40BC-96D5-CE6A698E4126 wds:Q96475433-447f3ac9-4e89-81a0-156c-ed70b69ab868
employer	wds:Q96475433-eb8cb04c-42a9-6f0c-8cba-e85bb4a4d537 wds:Q96475433-f9359261-48fc-b972-7271-410c454fe516
sex or gender	wds:Q96475433-5c9d556a-4c81-61ce-60f3-b11ab9caba4d
ISNI	wds:q96475433-239272f2-4037-6275-2d25-3962cab4cc68
VIAF ID	wds:Q96475433-4de7a84a-47e6-b7be-1d4a-c8274945b2f3
GND ID	wds:q96475433-9ad2820a-4785-830f-c6a4-a89ff2ffc5a4
country of citizenship	wds:Q96475433-68989700-4b72-958b-9ce3-12eab0e35f08
National Library of Spain ID	wds:q96475433-33271af8-44b4-1456-9d5d-b878f4622c77
VIAF ID	http://viaf.org/viaf/18008253
GND ID	https://d-nb.info/gnd/118014935
National Library of Spain ID	http://datos.bne.es/resource/XX5613299
occupation	oncologist researcher
employer	University of Tübingen University Medical Center Hamburg-Eppendorf
sex or gender	female organism
ISNI	0000000020561199
VIAF ID	18008253
GND ID	118014935
country of citizenship	Germany
National Library of Spain ID	XX5613299
ORCID iD	wds:Q96475433-FB773439-44CC-4BFE-9E0C-C1EC5E70E01F
Dimensions author ID	wds:Q96475433-A96877D6-859C-4321-B94D-F1B866B85D2E
ORCID iD	https://orcid.org/0000-0001-9422-6614
ORCID iD	0000-0001-9422-6614
Dimensions author ID	01342223545.37
is owl:sameAs of	Katja Weisel
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q96475433
is author of	Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: preliminary results Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study Genetic and functional characterization of isolated stromal cell lines from the aorta-gonado-mesonephros region Intravascular lymphoma - a rare cause of hemolytic anemia and neurologic disorders Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma Modulation of CXC chemokine receptor expression and function in human neutrophils during aging in vitro suggests a role in their clearance from circulation OP9 stroma augments survival of hematopoietic precursors and progenitors during hematopoietic differentiation from human embryonic stem cells Stromal cell lines from the aorta-gonado-mesonephros region are potent supporters of murine and human hematopoiesis Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Paraneoplastic granulocyte colony-stimulating factor secretion in soft tissue sarcoma mimicking myeloproliferative neoplasia: a case report Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. Can whole-body low-dose multidetector CT exclude the presence of myeloma bone disease in patients with monoclonal gammopathy of undetermined significance (MGUS)? Extended in vitro expansion of adult, mobilized CD34+ cells without significant cell senescence using a stromal cell coculture system with single cytokine support The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma Lenalidomide The BCL2 E17 and SP66 antibodies discriminate 2 immunophenotypically and genetically distinct subgroups of conventionally BCL2-"negative" grade 1/2 follicular lymphomas. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee. Increasing bone sclerosis during bortezomib therapy in multiple myeloma patients: results of a reduced-dose whole-body MDCT study. A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transpla Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR Dual-energy CT: virtual calcium subtraction for assessment of bone marrow involvement of the spine in multiple myeloma. Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software